. Author manuscript; available in PMC: 2020 Apr 4.

Published in final edited form as: Arch Pathol Lab Med. 2019 Aug 20;144(4):466–472. doi: 10.5858/arpa.2018-0526-OA

Table 1.

Summary of Findings in Marrow From Patients With Down Syndrome MDS and AML

			Dysplasia^b,c
Diagnosis	Cases	Blasts^a	MY	E	MK	MK Rings/Inclusions^b	Reticulin Fibrosis^b,d
MDS	60	11% (2%–17%)	6/60 (10%)	43/57 (75%)	55/58 (95%)	38/57 (67%)	25/25 (100%)
AML-MK	54	42% (20%–90%)	5/49 (10%)	26/46 (57%)	47/48 (98%)	27/46 (59%)	11/12 (92%)
AML-E	11	37% (22%–76%)	0/10 (0%)	9/10 (90%)	10/10 (100%)	4/8 (50%)	4/4 (100%)
AML-MK/E	20	54% (22%–90%)	0/19 (0%)	14/18 (78%)	19/19 (100%)	7/17 (41%)	6/6 (100%)
AML-U	10	51% (25%–90%)	1/10 (10%)	8/9 (89%)	9/10 (90%)	2/7 (29%)	5/5 (100%)
AML-NOS	7	43% (26%–75%)	0/6 (0%)	2/5 (40%)	4/5 (80%)	1/3 (33%)	1/1 (100%)

Abbreviations: AML, acute myeloid leukemia; AML-E, AML with erythroblastic differentiation; AML-MK, AML with megakaryoblastic differentiation; AML-MK/E, AML with mixed differentiation; AML-NOS, AML with insufficient information for sublineage assessment; AML-U, AML with no sublineage differentiation; E, erythroid; MDS, myelodysplastic syndrome; MK, megakaryocytic; MY, myeloid.

Mean (range).

Positive/evaluable (%).

Dysplasia = myelodysplastic morphologic features.^20,22

Fibrosis was defined as positive results with a reticulin stain. When present, fibrosis was grade 1/3 in the grading system of Thiele et al.²¹